Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Bayer CropScience Ltd    BAYERCROP   INE462A01022

No quotes available
-- INR   0.00%
07/28 BAYER CROPSCIEN : offers teachers free STEM workshop
07/06 BAYER CROPSCIEN : appoints Pankaj Patel as Chairman
06/21 BAYER CROPSCIEN : Advocacy group protests Bayer pesticide production..
SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Bayer CropScience : Research Conducted at Bayer CropScience Has Provided New Information about Hormones (Identification of selected in vitro generated phase-I...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/18/2016 | 09:46pm CEST

Research Conducted at Bayer CropScience Has Provided New Information about Hormones (Identification of selected in vitro generated phase-I metabolites of the steroidal selective androgen receptor modulator MK-0773 for doping control purposes)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Drugs and Therapies. According to news reporting from Monheim, Germany, by NewsRx journalists, research stated, "Research into developing anabolic agents for various therapeutic purposes has been pursued for decades. As the clinical utility of anabolic-androgenic steroids has been found to be limited because of their lack of tissue selectivity and associated off-target effects, alternative drug entities have been designed and are commonly referred to as selective androgen receptor modulators (SARMs)."

The news correspondents obtained a quote from the research from Bayer CropScience, "While most of these SARMs are of nonsteroidal structure, the drug candidate MK-0773 comprises a 4-aza-steroidal nucleus. Besides the intended therapeutic use, SARMs have been found to be illicitly distributed and misused as doping agents in sport, necessitating frequently updated doping control analytical assays. As steroidal compounds reportedly undergo considerable metabolic transformations, the phase-I metabolism of MK-0773 was simulated using human liver microsomal (HLM) preparations and electrochemical conversion. Subsequently, major metabolic products were identified and characterized employing liquid chromatography-high-resolution/high-accuracy tandem mass spectrometry with electrospray (ESI) and atmospheric pressure chemical ionization (APCI) as well as nuclear magnetic resonance (NMR) spectroscopy. MK-0773 produced numerous phase-I metabolites under the chosen in vitro incubation reactions, mostly resulting from mono-and bisoxygenation of the steroid. HLM yielded at least 10 monooxygenated species, while electrochemistry-based experiments resulted predominantly in three monohydroxylated metabolites. Elemental composition data and product ion mass spectra were generated for these analytes, ESI/APCI measurements corroborated the formation of at least two N-oxygenated metabolites, and NMR data obtained from electrochemistry-derived products supported structures suggested for three monohydroxylated compounds. Hereby, the hydroxylation of the A-ring located N-bound methyl group was found to be of particular intensity."

According to the news reporters, the research concluded: "In the absence of controlled elimination studies, the produced information enables the implementation of new target analytes into routine doping controls and expands the focus of anti-doping efforts concerning this new anabolic agent."

For more information on this research see: Identification of selected in vitro generated phase-I metabolites of the steroidal selective androgen receptor modulator MK-0773 for doping control purposes. European Journal of Mass Spectrometry, 2016;22(2):49-59 (see also Drugs and Therapies).

Our news journalists report that additional information may be obtained by contacting A. Lagojda, Bayer CropScience AG, Alfred-Nobel-Str 50, 40789 Monheim, Germany. Additional authors for this research include D. Kuehne, O. Krug, A. Thomas, T. Wigger, U. Karst, W. Schanzer and M. Thevis.

Keywords for this news article include: Europe, Monheim, Germany, Hormones, Chemicals, Electrochemistry, Drugs and Therapies, Androgens and Anabolic Steroids.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER CROPSCIENCE LTD
08/18 BAYER CROPSCIENCE : Research Conducted at Bayer CropScience Has Provided New Inf..
08/10 BAYER CROPSCIENCE : U.S. Patents Awarded to Inventors in Arkansas (Aug. 10)
08/10 BAYER CROPSCIENCE : Assigned Patent
08/04 BAYER CROPSCIENCE : Investigators at Bayer CropScience Discuss Findings in Amino..
07/28 BAYER CROPSCIENCE : offers teachers free STEM workshop
07/20 BAYER CROPSCIENCE : U.S. Patents Awarded to Inventors in Arkansas (July 20)
07/20 BAYER CROPSCIENCE : Assigned Patent
07/13 BAYER CROPSCIENCE : Assigned Patent
07/06 BAYER CROPSCIENCE : appoints Pankaj Patel as Chairman
07/06 BAYER CROPSCIENCE : Crop appoints pankaj patel as chairman
More news
Sector news : Agricultural Chemicals - NEC
08/24DJSYNGENTA : Seeds Deals Raise Concerns -- WSJ
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
08/23DJSYNGENTA : U.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
08/23DJSYNGENTA : Farmers Weigh In on Syngenta Deal -- WSJ
08/23DJSYNGENTA : U.S. Panel Approves Chinese Takeover -- WSJ
More sector news : Agricultural Chemicals - NEC
Advertisement
Financials ( INR)
Sales 2017 40 878 M
EBIT 2017 5 716 M
Net income 2017 4 226 M
Finance 2017 4 766 M
Yield 2017 0,53%
P/E ratio 2017 33,40
P/E ratio 2018 27,20
EV / Sales 2017 3,36x
EV / Sales 2018 2,86x
Capitalization 142 250 M
More Financials
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 3 925  INR
Spread / Average Target -2,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Richard van der Merwe Vice Chairman, Chief Executive Officer & MD
Ulrich Stefer Chief Financial Officer & Director
Sharad Madhav Kulkarni Independent Non-Executive Director
Ayani Kurussi Ravi Nedungadi Independent Non-Executive Director
Vimal Ranjeet Bhandari Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER CROPSCIENCE LTD0.00%2 120
SYNGENTA AG6.68%40 342
POTASH CORPORATION OF ..-8.72%13 945
AGRIUM INC.-3.19%12 641
UPL LTD47.33%10 083
YARA INTERNATIONAL ASA-24.26%9 831
More Results